The company's 2018 acquisition plans continue to be expected to take in 10 drugmakers

The company's 2018 acquisition plans are ongoing, with more than 10 nationally distributed pharmaceutical commercial or terminal retail businesses expected to cover at least 150,000 end-stores, community health care and clinics during the year.
yesterday (June 27), Jipharma Holdings announced that it would buy a 70 per cent stake in Liaoning Mero, a pharmaceutical commercial wholesale and distribution company.Liaoning Merro covers 14 county-level municipal grass-roots markets
announced that Ji Pharmaceutical Holdings Group Co., Ltd. recently signed an "equity transfer agreement" with Sun Xuewu, Zhou Changgui, Li Da, Liu Qian, Liu Guohua.
all parties agreed to transfer 70% of the shares of Liaoning Merro Pharmaceutical Supply Co., Ltd. to the company, the subject of the transaction 70% of the company's share price of 28 million yuan.
according to the announcement information, Liaoning Mero is a set of drugs, medical equipment, health food, cosmetics business in one integrated commercial wholesale and distribution enterprises.
At present, Liaoning Merrow has obtained more than 20 well-known domestic and foreign pharmaceutical manufacturers, including Pfizer, AstraZeneca, Merck, Lilly, Noel and Nord, in Liaoning Province, the first- and second-level distribution qualifications, the company is mainly in Liaoning Province 14 cities and county-level markets chain pharmacies, primary medical terminal distribution drugs, commercial distribution network can cover a number of provinces.
is notable for the timing of the acquisition. Liaoning Mero's financial data show a net loss of 4.08 million yuan in the January-March 2018 period.
nevertheless, Liaoning Merro has committed to net profit of not less than 4 million yuan, 4.4 million yuan and 4.8 million yuan per year after deducting non-recurring gains and losses in 2018, 2019 and 2020, i.e. the cumulative net profit after deducting non-recurring gains and losses in the next three years (2018-2020) is not less than 13.2 million yuan.1.2 billion yuan to receive two pharmaceutical industry enterprises
in addition, after The Pharmaceutical Holdings also announced plans to buy two pharmaceutical industry enterprises. One of them is Changchun PwY Pharmaceutical Co., Ltd.
according to the company's official website information, Changchun Puhua Pharmaceutical Co., Ltd. was founded in November 1997, mainly engaged in chinese medicine, chemicals research and development, production and sales. By the end of 2016, the company's total assets amounted to 228 million yuan, with net assets of 208 million yuan.
Changchun PwC Pharmaceuticals' business scope is mainly emulsions (containing hormones), granules, raw materials (mesatan hydrochloric acid, pyrethroids), drops, tablets, hard capsules, eye drops, small-volume injections, ointments, gels, antidotes, apidas (pepper base).
the transaction is expected to range from 750-850 million yuan.
company to be acquired is Tonghua Baiquan Group Co., Ltd.
, according to Cypress Blue understand, Tonghua Baiquan is a centralized cultivation of medicinal herbs, processing, sales and export trade as one of the integrated enterprises. Under its set up Tonghua Baiquan Import and Export Trading Co., Ltd., Tonghua Baiquan Chinese medicine drink tablets Co., Ltd., Tonghua Baiquan Health Food Co., Ltd.
December 13, 2012, the company officially changed its name to Tonghua Baiquan Participating Group Co., Ltd., and was successfully listed at the Shanghai Equity Custody Trading Center at the end of the same month, with a stake of 60 million shares.
to tonghua Baiquan ginseng business scope is mainly ginseng and Chinese herbal medicine cultivation, sales, health food sales and export trade.
the deal is expected to be RMB350 million to RMB400 million, with the expected deal in the form of the issuance of shares and the payment of cash. plans to lay out more than 10 drugmakers, covering 150,000 terminal stores
in fact, after the company's 2018 quarterly report revealed its possible acquisition plans for 2018.
according to the annual report, Jipal Holdings was established on the basis of its net assets as of November 30, 2007, and on the basis of the overall change of Tonghua Ssinglong Chemical Co., Ltd.
company was listed on the Shenzhen Stock Exchange on August 25, 2010 and changed its name to "Ji Pharmaceutical Holdings Co., Ltd." on October 16, 2017.
In its first quarter 2018 report, Jipharma Holdings plans to take end products as the lead in 2018 to carry out the acquisition and acquisition of pharmaceutical business, and plans to gradually form more than 10 national distribution and sales of pharmaceutical commercial or terminal retail enterprises in 2018, improve the construction of marketing network, continue to terminal chain pharmacies and terminal clinicSOTC sales as the main direction.
, Jipharma Holdings has completed the beijing, Anhui, Hunan, Henan, Jiangsu, Guangdong and other provinces in the second quarter to fully complete the pharmaceutical business platform network construction, the formation of terminal sales grid management and operation.
In addition, the quarterly report shows that in 2018, the sales business of Ji Pharmaceutical Holdings mainly revolves around the terminal large varieties and gold products as the main line, the implementation of three-level control and marketing management, the use of provincial pure sales commercial company platform to build, and gradually improve the product structure.
Antelope cough syrup, children's heat cough oral solution, hot poison flat particles, heat detox particles, through the painkiller wine, ginseng deer pills (double dosage form), pain relief capsules and OTC marketing product line to stroke prevention and rehabilitation treatment-based cerebral congestion pills, pro-brain rehabilitation capsule-based cardiovascular products are mainly in the end-community medical, terminal clinic sales line.
quarterly report, it is expected to cover at least 150,000 end-stores, community health care and clinics during the year. (Seber Blue)